Clinical Trials Directory

Trials / Conditions / Pulmonary Tuberculoses

Pulmonary Tuberculoses

16 registered clinical trials studyying Pulmonary Tuberculoses — 2 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingEvaluation of PATHFAST-LAM as a Tuberculosis Treatment Monitoring Tool in Kenya
NCT07157904
Nagasaki University—
RecruitingPhase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculo
NCT07073638
Thirty Respiratory LimitedPhase 2
UnknownA Retrospective Cohort Study to Develop Markers for TB Severity and Treatment Progress
NCT05477966
Jae-Joon Yim—
CompletedTime-to-Detection in Culture of Mycobacterium Tuberculosis
NCT05568368
Centre Hospitalier Universitaire de Nice—
UnknownSequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial
NCT05017324
Universiteit AntwerpenN/A
UnknownEffect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tubercu
NCT04930978
Tuberculosis Research Centre, India—
CompletedEconomic Evaluation of New MDR TB Regimens
NCT04207112
Medecins Sans Frontieres, NetherlandsPhase 2 / Phase 3
CompletedEvaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resist
NCT03896685
Médecins Sans Frontières, FrancePhase 3
Active Not RecruitingPulmonary Aspergillosis in Tuberculosis Patients
NCT05045391
Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan—
CompletedBTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)
NCT04044001
Michael HoelscherPhase 1 / Phase 2
CompletedPrevalence and Burden of Bronchiectasis in Tuberculous Patients
NCT04085133
Assiut University—
WithdrawnSafety and Immunogenicity Study of GX-70 in TB Patient
NCT03159975
Yonsei UniversityPhase 1
CompletedLung Health After Tuberculosis: Clinical and Functional Assessment in Post Pulmonary Tuberculosis Egyptian Pat
NCT05097638
Assiut University—
CompletedEvaluating Newly Approved Drugs for Multidrug-resistant TB
NCT02754765
Médecins Sans Frontières, FrancePhase 3
CompletedLine Probe Assay Evaluation Study
NCT02984579
Foundation for Innovative New Diagnostics, Switzerland—
Active Not RecruitingVitamin D and Immune Response in Pulmonary Tuberculosis With and Without Chronic Pulmonary Aspergillosis
NCT07516158
Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan—